US20130317218A1 - Novel bicyclic thiazole compounds - Google Patents

Novel bicyclic thiazole compounds Download PDF

Info

Publication number
US20130317218A1
US20130317218A1 US13/479,396 US201213479396A US2013317218A1 US 20130317218 A1 US20130317218 A1 US 20130317218A1 US 201213479396 A US201213479396 A US 201213479396A US 2013317218 A1 US2013317218 A1 US 2013317218A1
Authority
US
United States
Prior art keywords
group
thiazole
carboxamide
substituted
ylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/479,396
Other languages
English (en)
Inventor
Masaaki Sawa
Hideki Moriyama
Tesshi Yamada
Miki Shitashige
Yusuke Kawase
Yuko Uno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US13/479,396 priority Critical patent/US20130317218A1/en
Priority to EP13729492.2A priority patent/EP2855470B1/en
Priority to KR1020147032428A priority patent/KR102042296B1/ko
Priority to PCT/JP2013/064960 priority patent/WO2013176293A1/en
Priority to JP2014556280A priority patent/JP6095195B2/ja
Priority to CN201380026183.8A priority patent/CN104321321B/zh
Priority to US14/403,071 priority patent/US9102637B2/en
Publication of US20130317218A1 publication Critical patent/US20130317218A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to novel bicyclic thiazole compounds that inhibit Traf2- and Nck-interacting kinase (TNIK), and as such are useful as TNIK inhibitors administered to cancer patients, especially to solid cancer patients such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer.
  • TNIK Traf2- and Nck-interacting kinase
  • Wnt proteins constitute a large family of secreted glycoproteins that activate signal transduction pathways to control a wide variety of cellular processes such as determination of cell fate, proliferation, migration, and polarity. Wnt proteins are capable of signaling through several pathways, the best-characterized being the canonical pathway through ⁇ -catenin (Wnt/ ⁇ -catenin signaling). Deregulation of Wnt/ ⁇ -catenin signaling is frequently found in many human cancers like colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer, breast cancer, and many others.
  • TNIK is known as one of STE20 family kinases that activates the c-Jun N-terminal kinase pathway and regulates the cytoskeleton. Recently, TNIK was identified as one of 70 proteins immunoprecipitated commonly with anti-TCF4 (T-cell factor-4) and anti- ⁇ -catenin antibodies in two colorectal cancer cell lines DLD1 and HCT-116 (Shitashige M, et al., Gastroenterology 2008, 134:1961-71).
  • TNIK plays critical roles in canonical Wnt signaling pathway, and therefore TNIK can be a promising target to ablate aberrant Wnt signaling in tumors (Shitashige M, et al., Cancer Res; 70(12); 5024-33 (2010)). Namely, small interfering RNA targeting TNIK inhibited the proliferation of colorectal cancer cells and the growth of tumors produced by injecting colorectal cancer cells s.c. into immunodeficient mice.
  • This invention provides novel bicyclic thiazole compounds that inhibit TNIK, and as such are useful as TNIK inhibitors administered to cancer patients, especially to solid cancer patients such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer.
  • the present invention provides compounds that have the formula (I):
  • each of A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 is, independently C-Z or N
  • R 2 is a hydrogen atom, a substituted or unsubstituted alkyl group
  • R 3 is a hydrogen atom, a substituted or unsubstituted alkyl group, a hydroxyl group, a substituted or unsubstituted alkoxy group
  • each of Y 1 , Y 2 , Y 3 and Y 4 is, independently represent a nitrogen atom optionally substituted with hydrogen atom or lower alkyl group, sulfur atom, oxygen atom or carbon atom
  • Z, R 4 and R 5 independently represent a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a hydroxyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, a carboxyl group, a ester group, a formyl group, a substituted carbonyl group, a substituted carbamoyl group, a substituted or unsubstituted urea group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted acylamino group,
  • the substituent as used herein includes, for example, a halogen atom (such as F, Cl, Br), a substituted or unsubstituted alkyl group (such as a substituted or unsubstituted C1-C6 alkyl group, a substituted or unsubstituted C3-C7 cycloalkyl group, a substituted or unsubstituted aralkyl group, wherein the substituent includes, for example, hydroxyl group, dimethylamino group, morpholino group, 4-methylpiperazin-1-yl group and piperazin-1-yl group.), a substituted or unsubstituted alkoxy group (such as a substituted or unsubstituted C1-C6 alkoxy group), a substituted or unsubstituted amino group (such as amino group, morpholino group or 4-methylpiperazin-1-yl group), a substituted or unsubstituted acylamino group (such as
  • Any compound of any formula disclosed herein can be obtained using procedures provided in the reaction Schemes, as well as procedures provided in the Examples, by selecting suitable starting materials and following analogous procedures.
  • any compound of any formula disclosed or exemplified herein can be obtained by using the appropriate starting materials and appropriate reagents, with the desired substitutions, and following procedures analogous to those described herein.
  • R 1 , R 3 , and Q are the same as defined in the formula (I).
  • amide-coupling reaction may be done with a carboxylic acid (III-b) under general amide coupling conditions such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), hydroxybenzotriazole (HOBT) and a base such as diisopropylethylamine or triethylamine to afford the compounds of formula (I) wherein R 2 is a hydrogen atom.
  • EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
  • HOBT hydroxybenzotriazole
  • base such as diisopropylethylamine or triethylamine
  • compounds of formula (I) may be prepared from the ester intermediate (IV) by a direct aminolysis with amines, as shown in Scheme 2:
  • R 1 , R 2 , R 3 , and Q are the same as defined in the formula (I).
  • the aminolysis reaction is carried out by using a neat amine solution or an amine in an alcohol solution in presence of a solvent such as THF, or dioxane.
  • the reaction is stirred and heated in a sealed tube at a temperature from 80° C. to 150° C., for 1-24 hours, preferably under microwave irradiation at 80° C. for 150 minutes using a microwave synthesizer.
  • compounds of formula (I) can be made by N-alkylation of compound of formula (I) having R 2 being hydrogen using well-known synthetic route such as reductive alkylation or alkylation with alkyl halides in case the functionalization of the molecule is compatible with this type of reactions.
  • R 1 , R 2 , R 3 , and Q are the same as defined in the formula (I) and X is a halogen selected from Cl, Br and I.
  • the compounds represented by the formula (II) in Scheme 1, which are used as starting materials of the amide-coupling reaction, may be prepared in a similar manner as described by Cook et al. (J. Chem. Soc. 1949, 3001).
  • the compounds represented by the formula (II) may be prepared by the Scheme 4 below:
  • R 1 and R 3 are the same as defined in the formula (I).
  • the isothiocyanate (V) may be commercially available, or may be prepared from the corresponding amine by the methods well known in the field of organic synthesis, such as a thiophosgene treatment.
  • the isothiocyanate (V) also can be prepared from the corresponding halides with silver (I) thiocyanate in a similar manner as described by Zhong et al. (Tetrahedron Letters, 47(13), 2161-2164 (2006)).
  • ester intermediate (IV) may be prepared via a palladium-catalyzed reaction with an amine (VII) and 2-halogeno-thiazole compound (VI), as shown in Scheme 5:
  • R 1 , R 2 , and Q are the same as defined in the formula (I) and X is a halogen selected from Cl, Br and I.
  • Buchwald/Hartwig type reactions are well-known to those skilled in the art and are performed in inert solvents such as toluene, THF or dioxane and involve a palladium catalyst such as tris(dibenzylideneacetone)dipalladium (0), tetrakis(triphenylphosphine)palladium (0), palladium (II) acetate, and a base such as sodium, potassium or cesium carbonate, and a ligand such as 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene (XANTPHOS).
  • the same type of palladium-coupling reaction may be done with a corresponding halogeno-aromatic/heteroaromatic compound and a corresponding 2-aminothiazole analog to give the same desired aminothiazole intermediates (IV).
  • the compound represented by the formula (VI) may be synthesized by the formation of the amide from 5-aminothiazole intermediate (VIII) and an acid chloride (III-a).
  • the same type of amide-coupling reaction may be done with a carboxylic acid (III-b) under general amide coupling conditions such as EDC, HOBT and a base such as diisopropylethylamine, or triethylamine
  • the compound represented by the formula (VIII) may be prepared from 5-aminothiazole-4-carboxylic acid ethyl ester by the Scheme 7 below:
  • X is a halogen selected from Cl, Br and I.
  • 5-Aminothiazole-4-carboxylic acid ethyl ester is prepared according to the procedure described by Golankiewicz et al. (Tetrahedron, 41 (24), 5989-5994 (1985)).
  • ethyl cyano(hydroxyimino)acetate is treated with sodium dithionate in sat. sodium bicarbonate aqueous solution to give ethyl 2-amino-2-cyanoacetate, which is then converted to the corresponding formamide with acetic formic anhydride.
  • the obtained ethyl 2-cyano-2-formamidoacetate is treated with Lawesson's reagent, followed by treating with a halogenation reagent such as NCS, NBS to give the desired product.
  • a halogenation reagent such as NCS, NBS
  • the bicyclic thiazole compounds (I) or a pharmaceutically acceptable salt thereof show the TNIK inhibitory effects (Test Example 1) and a remarkable antiproliferative activity (Test Example 2).
  • the bicyclic thiazole compounds may be used as a pharmaceutical composition (for example an anti-tumor agent) in the form of a conventional pharmaceutical preparation for an oral or parenteral administration such as intravenous drip injection.
  • the preparation for oral administration includes solid preparations such as tablets, granules, powders, capsules, and liquid preparations such as syrups. These preparations can be prepared by a conventional method.
  • the solid preparations can be prepared by using conventional pharmaceutical carriers, such as lactose, starch such as cornstarch, crystalline cellulose such as microcrystalline cellulose, hydroxypropyl cellulose, calcium carboxymethylcellulose, talc, magnesium stearate, etc.
  • Capsules can be prepared by capsulating the granules or powders thus prepared.
  • Syrups can be prepared by dissolving or suspending the bicyclic thiazole compounds in an aqueous solution containing sucrose, carboxymethylcellulose, etc.
  • the preparation for parenteral administration includes injections such as intravenous drip injection.
  • the injection preparation can also be prepared by a conventional method, and optionally may be incorporated in isotonic agents (e.g. mannitol, sodium chloride, glucose, sorbitol, glycerol, xylitol, fructose, maltose, mannose), stabilizers (e.g. sodium sulfite, albumin), preservatives (e.g. benzyl alcohol, methyl p-hydroxybenzoate).
  • isotonic agents e.g. mannitol, sodium chloride, glucose, sorbitol, glycerol, xylitol, fructose, maltose, mannose
  • stabilizers e.g. sodium sulfite, albumin
  • preservatives e.g. benzyl alcohol, methyl p-hydroxybenzoate.
  • the bicyclic thiazole compounds are effective for the treatment of tumors, especially solid tumors such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer.
  • the dose of the bicyclic thiazole compounds may vary according to the severity of the diseases, ages and body weights of the patients, dosage forms and the like, but is usually in the range of 1 mg-1,000 mg per day in an adult, which may be administered once or by dividing into two or three times by the oral or parenteral route.
  • a cDNA encoding the N-terminal segment (TNIK_N, residues 1-314) containing the kinase domain of human TNIK (NM — 015028.1) was amplified from cDNA mixture synthesized from human tissue (Biochain) by PCR using the following primers.
  • Forward primer, 40 nucleotides including a EheI site (described as SEQ ID NO. 1 in “Preparation of recombinant human TNIK (N-terminal segment)” of WO 2010/064111 (P.29))
  • Reverse primer 42 nucleotides including a NotI site (described as SEQ ID NO. 2 in “Preparation of recombinant human TNIK (N-terminal segment)” of WO 2010/064111 (P.29)).
  • the cDNA was subcloned into baculovirus transfer vector pFastBac_GSTb that includes protease cleavage site and glutathione S-transferase purification tag (GST-tag).
  • the plasmid was purified and the insertion of the pFastBac_GSTb-TNIK_N was confirmed by DNA sequencing.
  • E. coli DH10Bac competent cells were transformed with the plasmid to prepare the recombinant bacmid according to the instructions for the Bac-to-BacTM baculovirus expression systems (Invitrogen).
  • the Sf9 cells were transfected with the recombinant bacmid containing pFastBac_GSTb-TNIK_N using Cellfectin Reagent (Invitrogen) in SF-900II serum free media (Invitrogen).
  • the viral supernatant was collected from the medium 72 h after transfection.
  • the virus was amplified three times by infecting actively growing Sf9 or Sf21 cells in Grace's insect media (Invitrogen) supplemented with 10% FCS and an antibiotic-antimycotic reagent (Invitrogen) for 72 h at 27° C. in T-flask or roller bottles.
  • the titer of amplified TNIK_N virus was estimated at 2.36 ⁇ 10 8 pfu/ml by using BacPAKTM Baculovirus Rapid Titer kit (Clontech).
  • Log-phase Sf21 cells (2 ⁇ 10 6 cells/ml) in the Grace's insect media were infected with the recombinant baculovirus at MOI of 3.0 and incubated in roller bottles (250 ml media per bottle) for 72 h at 27° C., after which, the cells were collected by centrifugation, and the cell pellet washed with cold PBS and kept at ⁇ 80° C. until purification. The following purification procedures were carried out at 4° C.
  • the frozen cells were thawed on ice and lysed in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 5 mM DTT, 0.5 mM EDTA, 0.5 mM EGTA) supplemented with 1 mM phenylmethansulfonylfluoride, 2 ⁇ g/ml leupeptin, 2 ⁇ g/ml aprotinin, 1 mM NaF, 100 ⁇ M sodium orthovanadate, and 1 ⁇ M cantharidin by sonication.
  • lysis buffer 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 5 mM DTT, 0.5 mM EDTA, 0.5 mM EGTA
  • the suspended lysate was cleared by centrifugation at 9000 g for 20 min and the supernatant was incubated for 1 h with glutathione Sepharose beads (GE Healthcare).
  • the beads were suspended in buffer-H (50 mM Tris-HCl, pH 7.5, 1 M NaCl, 1 mM DTT, 0.5 mM EDTA, 0.5 mM EGTA and 0.05% Brij35) and washed with buffer-H followed by buffer-L (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM DTT, 0.5 mM EDTA, 0.5 mM EGTA, 0.05% Brij35) in an Econo-pack column (BIO-RAD).
  • buffer-H 50 mM Tris-HCl, pH 7.5, 1 M NaCl, 1 mM DTT, 0.5 mM EDTA, 0.5 mM EGTA, 0.05% Brij35
  • the bound TNIK_N was eluted with elution buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM DTT, 10% glycerol, 0.5 mM EDTA, 0.5 mM EGTA and 5 mM reduced glutathione). The eluted fractions were collected and determined the protein concentration by Bradford reagent (BIO-RAD). The TNIK_N fractions were pooled and desalted using 10DG column (BIORAD) equilibrated with the storage buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM DTT, 10% glycerol, 0.05% Brij35).
  • TNIK_N The purified TNIK_N was characterized by electrophoresis using 4-20% polyacrylamide gels and matrix-assisted laser desorption/ionization reflection time-of-flight (MALDI-TOF) mass spectrometry on a Voyager-DE RP MALDI/TOF (Applied Biosystems). TNIK_N was confirmed by the molecular weight and MASCOT Peptide Mass Fingerprint.
  • MALDI-TOF matrix-assisted laser desorption/ionization reflection time-of-flight
  • the kinase assays were conducted in a 20 ⁇ l volume using 384-well plates (Greiner).
  • the reaction mixture consists of compound or vehicle (1% DMSO), 0.08 ng/ ⁇ l TNIK_N, 1 ⁇ M FITC-labeled substrate peptides, including ⁇ -aminocaproic acid and 7 amino acids (described as SEQ ID NO. 3 in “Kinase assay of TEST EXAMPLE 1” of WO 2010/064111(P.31)), 20 mM Hepes, pH 7.5, 0.01% Triton X-100, 5 mM MgCl 2 , 25 ⁇ M ATP and 2 mM DTT.
  • TNIK_N was excluded from the reaction mixture of vehicle (1% DMSO).
  • the kinase reaction was carried out 1 h at room temperature and terminated by addition of 60 ⁇ l of the termination buffer (127 mM Hepes, pH 7.5, 26.7 mM EDTA, 0.01% Triton X-100, 1% DMSO and 0.13% Coating Reagent 3 (Caliper Life Sciences)).
  • the amount of unphosphorylated and phosphorylated FITC-labeled substrate peptides was detected by Mobility Shift Micro Fluidic Technology (Caliper LC3000 System, Caliper Life Sciences).
  • the kinase activity of TNIK_N was defined as P/(P+S) (P: peak height of the phosphorylated FITC-labeled substrate peptide; S: peak height of the FITC-labeled substrate peptide).
  • the IC50 values of the compound against the kinases were calculated from regression analysis of the log-concentration-inhibition curves.
  • the human colon cancer cell line HCT-116 was seeded at 600 cells/well in 96 well-plate (ThermoFisher) using RPMI medium containing 2 mM L-glutamine (Invitrogen) supplemented with 10% FCS (Invitrogen) and 1% penicillin/streptomycin (Sigma) and maintained at 37° C., 5% CO 2 and 100% humidity. The following day, old medium was withdrawn and the fresh medium was added. Initial numbers of cells were counted before adding compounds. Then cells were treated in duplicates with compounds (a half-logarithmic serial dilution from 10 ⁇ M). Eight untreated control wells were incubated in each plate.
  • POCl 3 phosphorous oxychloride
  • Pd 2 (dba) 3 Tris(dibenzylideneacetone)dipalladium(0)
  • THF tetrahydrofuran
  • TFA trifluoroacetic acid
  • Xantphos 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene
  • EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
  • HOBT hydroxybenzotriazole min: minute(s) h or hr(s): hour(s) RT or rt: room temperature sat.: saturated aq.: aqueous
  • TLC thin layer chromatography
  • HPLC high performance liquid chromatography
  • Prep HPLC preparative HPLC LCMS: high performance liquid chromatography/mass spectrometry
  • MS mass spectrometry
  • NMR nuclear magnetic resonance
  • reaction mixture was diluted with ethyl acetate (150 mL), washed with water, and dried over Na 2 SO 4 .
  • the solvent was evaporated under reduced pressure, and the crude residue was purified by silica gel column chromatograph eluted with 5% MeOH in DCM to give 0.010 g (11% yield) of the titled compound.
  • reaction mixture was diluted with ethyl acetate (150 mL), washed with water, and dried over Na 2 SO 4 .
  • the solvent was evaporated under reduced pressure, and the crude residue was purified by silica gel column chromatography eluted with 5% MeOH in DCM to give 0.010 g (11% yield) of the titled compound.
  • 1,1′-Thiocarbonyldiimidazole (740 mg, 4.16 mmol) was added portion-wise to a solution of quinolin-6-amine (0.50 g, 3.47 mmol) in DCM (15 mL) at 0° C., and the mixture was stirred at rt for 1.5 hrs. The reaction mixture was concentrated in vacuo, and the residue was purified by column chromatography eluted with DCM to give 0.60 g (93% yield) of the titled compound.
  • N-Bromosuccinimide (0.54 g, 3.03 mmol) was added to a solution of 5-aminothiazole-4-carboxylic acid ethyl ester (0.44 g, 2.53 mmol) [prepared according to the procedure described by Golankiewicz et al. (Tetrahedron, 41 (24), 5989-5994 (1985))] in acetonitrile (10 mL), and the mixture was stirred for 30 min. The reaction mixture was diluted with EtOAc (50 mL) and washed with 5% K 2 CO 3 aq. solution (25 mL) followed by brine (25 mL). The organic layer was dried over Na 2 SO 4 and concentrated. The residue was purified by silica gel column chromatography eluted with 15% EtOAc in hexane to give 0.37 g (58% yield) of the titled compound.
  • the compound of example 2 cornstarch and microcrystalline cellulose are mixed and the mixture is added to hydroxypropyl cellulose dissolved in 50 parts by weight of water, followed by sufficient kneading.
  • the kneaded mixture is passed through a sieve to granulate, dried mixed with magnesium stearate and then compressed into tablets of 250 mg each.
  • the compound of example 2 lactose and cornstarch are mixed and the mixture is added to hydroxypropyl cellulose dissolved in 120 parts by weight of water, followed by sufficient kneading.
  • the kneaded mixture is passed through a 20 mesh sieve to granulate, dried and then size-adjusted to obtain granules containing 200 mg of Compound of example 2 per 500 mg of granule.
  • lactose, cornstarch and magnesium stearate are well mixed and 200 mg each of the powder mixture is encapsulated to obtain capsules.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
US13/479,396 2012-05-24 2012-05-24 Novel bicyclic thiazole compounds Abandoned US20130317218A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US13/479,396 US20130317218A1 (en) 2012-05-24 2012-05-24 Novel bicyclic thiazole compounds
EP13729492.2A EP2855470B1 (en) 2012-05-24 2013-05-22 Novel bicyclic thiazole compounds
KR1020147032428A KR102042296B1 (ko) 2012-05-24 2013-05-22 신규한 비시클릭 티아졸 화합물
PCT/JP2013/064960 WO2013176293A1 (en) 2012-05-24 2013-05-22 Novel bicyclic thiazole compounds
JP2014556280A JP6095195B2 (ja) 2012-05-24 2013-05-22 新規二環式チアゾール化合物
CN201380026183.8A CN104321321B (zh) 2012-05-24 2013-05-22 二环噻唑类化合物
US14/403,071 US9102637B2 (en) 2012-05-24 2013-05-22 Bicyclic thiazole compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/479,396 US20130317218A1 (en) 2012-05-24 2012-05-24 Novel bicyclic thiazole compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/403,071 Continuation US9102637B2 (en) 2012-05-24 2013-05-22 Bicyclic thiazole compounds

Publications (1)

Publication Number Publication Date
US20130317218A1 true US20130317218A1 (en) 2013-11-28

Family

ID=48628877

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/479,396 Abandoned US20130317218A1 (en) 2012-05-24 2012-05-24 Novel bicyclic thiazole compounds
US14/403,071 Expired - Fee Related US9102637B2 (en) 2012-05-24 2013-05-22 Bicyclic thiazole compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/403,071 Expired - Fee Related US9102637B2 (en) 2012-05-24 2013-05-22 Bicyclic thiazole compounds

Country Status (6)

Country Link
US (2) US20130317218A1 (ja)
EP (1) EP2855470B1 (ja)
JP (1) JP6095195B2 (ja)
KR (1) KR102042296B1 (ja)
CN (1) CN104321321B (ja)
WO (1) WO2013176293A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9102637B2 (en) 2012-05-24 2015-08-11 Carna Biosciences, Inc. Bicyclic thiazole compounds
WO2016202935A1 (en) * 2015-06-19 2016-12-22 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108474981B (zh) * 2015-10-14 2021-04-16 日产化学工业株式会社 液晶取向剂、液晶取向膜和液晶表示元件
WO2024111626A1 (ja) * 2022-11-25 2024-05-30 カルナバイオサイエンス株式会社 新規チアゾール誘導体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4038661B2 (ja) * 2002-05-21 2008-01-30 株式会社大塚製薬工場 ホスホン酸ジエステル誘導体
US8323943B2 (en) * 2008-02-21 2012-12-04 National Cancer Center Screening method for anticancer drug
US20100137386A1 (en) 2008-12-01 2010-06-03 Tesshi Yamada Tnik inhibitor and the use
US20130317218A1 (en) 2012-05-24 2013-11-28 Masaaki Sawa Novel bicyclic thiazole compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9102637B2 (en) 2012-05-24 2015-08-11 Carna Biosciences, Inc. Bicyclic thiazole compounds
WO2016202935A1 (en) * 2015-06-19 2016-12-22 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors

Also Published As

Publication number Publication date
EP2855470A1 (en) 2015-04-08
US9102637B2 (en) 2015-08-11
CN104321321B (zh) 2017-07-07
KR102042296B1 (ko) 2019-11-07
JP6095195B2 (ja) 2017-03-15
US20150133656A1 (en) 2015-05-14
WO2013176293A1 (en) 2013-11-28
KR20150014931A (ko) 2015-02-09
CN104321321A (zh) 2015-01-28
EP2855470B1 (en) 2018-10-17
JP2015517453A (ja) 2015-06-22

Similar Documents

Publication Publication Date Title
EP2157091B1 (en) Inhibitors of phosphatidylinositol 3-kinase
EP1430051B1 (en) N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n-phenylamines as antiproliferative compounds
WO2013027168A1 (en) Novel heterocyclic compounds as bromodomain inhibitors
US20070117800A1 (en) Pyrimidinyl-thiophene kinase modulators
US20080269238A1 (en) Thiazolopyrimidine Derivative
US20100298324A1 (en) Prolyl Hydroxylase Inhibitors
AU2021269397B2 (en) Compounds and compositions for the treatment of cancer
NZ540161A (en) Compositions useful as inhibitors of rock and other protein kinases
SK2082002A3 (en) 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents
JP2006514684A5 (ja)
JP5769326B2 (ja) Ｒｈｏキナーゼ阻害薬
US9102637B2 (en) Bicyclic thiazole compounds
EP2364149B1 (en) Tnik inhibitor and the use
CA2631051A1 (en) Organic compounds
US20090203692A1 (en) Novel chemical compounds
US20100216795A1 (en) Tnik inhibitor and the use
MX2008007677A (en) Organic compounds

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION